title: Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
abstract: In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated interferon (PEG-IFN) alpha-2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for a fixed duration of 48 weeks (control group, n = 50) or for a variable duration (n = 318). In the variable-duration group, patients with undetectable HCV RNA at week 4 were treated for 24 weeks (group A, n = 69), patients with undetectable HCV RNA at week 12 were treated for 36 weeks (group B, n = 79), and the rest of the patients were treated for 48 weeks (group C, n = 160). The primary endpoint was SVR (undetectable HCV RNA 24 weeks after treatment cessation). Groups A-C and the control group had SVR rates of 86%, 76%, 56%, and 58%, respectively. After the study was controlled for predictors, a low baseline histologic grade and stage were associated with SVR (P < 0.029) in all groups. In addition, among patients in group C, older age (P = 0.04), a higher baseline body mass index (P = 0.013), and low baseline HCV RNA (P < 0.001) were also associated with SVR attainment. The incidence of adverse events and the rate of discontinuation were higher in patients in the variable-duration and fixed-duration groups treated for 48 weeks.
  
  
  CONCLUSIONS
  In patients with chronic hepatitis C genotype 4 and undetectable HCV RNA at weeks 4 and 12, treatment with PEG-IFN alpha-2b and ribavirin for 24 weeks and 36 weeks, respectively, is sufficient.
authors.affiliation: Department of Gastroenterology and Hepatology, Ain Shams University, Cairo, Egypt. sanaa.kamal@link.net
authors.forename: Sanaa M
authors.initials: SM
authors.lastname: Kamal
authors.forename: Samer S
authors.initials: SS
authors.lastname: El Kamary
authors.forename: Michelle D
authors.initials: MD
authors.lastname: Shardell
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hashem
authors.forename: Imad N
authors.initials: IN
authors.lastname: Ahmed
authors.forename: Mohamed
authors.initials: M
authors.lastname: Muhammadi
authors.forename: Khalifa
authors.initials: K
authors.lastname: Sayed
authors.forename: Ashraf
authors.initials: A
authors.lastname: Moustafa
authors.forename: Sarah Abdel
authors.initials: SA
authors.lastname: Hakem
authors.forename: Amany
authors.initials: A
authors.lastname: Ibrahiem
authors.forename: Mohamed
authors.initials: M
authors.lastname: Moniem
authors.forename: Hoda
authors.initials: H
authors.lastname: Mansour
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdelaziz
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b